Brief: Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses And Favorable Safety Profile For Miv-Cel In Stiff Person Syndrome And Generalized Myasthenia Gravis
24/09/2026 11:02
BRIEF-Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses And Favorable Safety Profile For Miv-Cel In Stiff Person Syndrome And Generalized Myasthenia Gravis Sept 24 (Reuters) - Kyverna Therapeutics, Inc. KYTX.O:
KYVERNA THERAPEUTICS REPORTS POSITIVE ONE-YEAR DATA DEMONSTRATING DURABLE CLINICAL RESPONSES AND FAVORABLE SAFETY PROFILE FOR MIV-CEL IN STIFF PERSON SYNDROME AND GENERALIZED MYASTHENIA GRAVIS
KYVERNA THERAPEUTICS, - MIV-CEL WELL-TOLERATED IN GMG TRIAL WITH NO HIGH-GRADE CRS, ICANS, OR IEC-HS
KYVERNA THERAPEUTICS, - PHASE 3 KYSA-6 TRIAL ENROLLMENT EXPECTED TO BE COMPLETED IN MID-2027
Source text: ID:nGNXbZfW8W
Further company coverage: KYTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kyverna Therapeutics
See all newsHealth Rounds: Appendix removal linked with lower colon cancer risk in study
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry
U.S. STOCKS ON THE MOVE-Everpure, Dropbox, Darden Restaurants